NASDAQ:EXEL Exelixis (EXEL) Stock Price, News & Analysis $65.71 -2.58 (-3.78%) As of 03:35 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Exelixis Stock (NASDAQ:EXEL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Exelixis alerts:Sign Up Key Stats Today's Range$65.36▼$68.5050-Day Range$56.12▼$72.7552-Week Range$39.71▼$73.69Volume1.79 million shsAverage Volume2.62 million shsMarket Capitalization$16.03 billionP/E Ratio19.65Dividend YieldN/APrice Target$58.62Consensus RatingHold Company Overview Exelixis, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for cancer. Founded in 1994 and headquartered in Alameda, California, the company has built its business around oncology treatments and continues to advance a pipeline of potential cancer therapies. Its principal marketed medicine is cabozantinib, sold in the United States as Cabometyx and Cometriq. Cabometyx is used to treat certain patients with advanced kidney, liver and thyroid cancers, while Cometriq is used for medullary thyroid cancer. Exelixis also develops additional targeted therapies and investigates new uses for its medicines. Exelixis commercializes products in the United States and works with pharmaceutical partners to make certain medicines available in other markets. The company is led by President and Chief Executive Officer Michael M. Morrissey, who has held the role since 2016.AI Generated. May Contain Errors. Read More Exelixis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreEXEL MarketRank™: 2.264485344235 of 5 starsExelixis scored higher than 45% of companies evaluated by MarketBeat, and ranked 1195th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingExelixis has received a consensus rating of Hold. The company's average rating score is 2.41, and is based on 1 strong buy rating, 6 buy ratings, 9 hold ratings, and 1 sell rating.Downside RiskExelixis has a consensus price target of $58.62, representing about 11.0% downside from its current price of $65.87.Amount of Analyst CoverageExelixis has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Exelixis' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth11.11% Earnings GrowthEarnings for Exelixis are expected to grow by 11.11% in the coming year, from $3.42 to $3.80 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exelixis is 19.72, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.78.Price to Earnings Ratio vs. SectorThe P/E ratio of Exelixis is 19.72, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.98.Price to Earnings Growth RatioExelixis has a PEG Ratio of 1.77. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioExelixis has a P/B Ratio of 8.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.77% of the float of Exelixis has been sold short.Short Interest Ratio / Days to CoverExelixis has a short interest ratio ("days to cover") of 11.71, which indicates bearish sentiment.Change versus previous monthShort interest in Exelixis has recently decreased by 6.30%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldExelixis does not currently pay a dividend.Dividend GrowthExelixis does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.24 News SentimentExelixis has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Exelixis this week, compared to 8 articles on an average week.Search InterestOnly 12 people have searched for EXEL on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows10 people have added Exelixis to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Exelixis insiders have not sold or bought any company stock.Percentage Held by Insiders2.60% of the stock of Exelixis is held by insiders.Percentage Held by Institutions85.27% of the stock of Exelixis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exelixis' insider trading history. Receive EXEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EXEL Stock News HeadlinesExelixis: Management's $5 Billion Aspiration Is Already In The Share Price2 hours ago | seekingalpha.comShould You Buy Exelixis Stock For Its Cash?November 19 at 7:46 AM | finance.yahoo.comELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.November 19 at 1:00 AM | Paradigm Press (Ad)Exelixis Eyes Turning Point as Colorectal Cancer Drug Decision NearsNovember 18 at 1:13 AM | americanbankingnews.comExelixis, Inc. (EXEL) Presents at UBS Global Biopharma Conference 2026 TranscriptNovember 17 at 6:42 AM | seekingalpha.comWhere Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change EverythingNovember 16 at 5:10 PM | fool.comWhere Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change EverythingNovember 16 at 4:32 PM | fool.comBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock (EXEL)Bristol-Myers Squibb's iza-bren cut breast cancer progression risk by up to 38% in a Phase 3 trial, lifting shares and raising implications for rivals like Exelixis.October 26, 2026 | marketbeat.comSee More Headlines EXEL Stock Analysis - Frequently Asked Questions How have EXEL shares performed this year? Exelixis' stock was trading at $43.83 on January 1st, 2026. Since then, EXEL stock has increased by 50.3% and is now trading at $65.8690. How were Exelixis' earnings last quarter? Exelixis, Inc. (NASDAQ:EXEL) issued its quarterly earnings data on Thursday, October, 29th. The biotechnology company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.89 by $0.05. Exelixis's quarterly revenue was up 10.2% compared to the same quarter last year. Read the conference call transcript. Who are Exelixis' major shareholders? Exelixis' top institutional shareholders include State Street Corp (4.31%), First Trust Advisors LP (1.16%), Stephens Investment Management Group LLC (1.06%) and Allspring Global Investments Holdings LLC (1.00%). Insiders that own company stock include David Edward Johnson, Stelios Papadopoulos, Christopher J Senner, Jeffrey Hessekiel, Dana Aftab, Amy C Peterson, Patrick J Haley, Jack L Wyszomierski, George Poste, Brenda Hefti, Brenda Hefti, Maria C Freire, Maria C Freire, Alan M Garber, Tomas J Heyman, Bob Oliver, Sue Gail Eckhardt and Mary C Beckerle. View institutional ownership trends. How do I buy shares of Exelixis? Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Exelixis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Exelixis investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), Bristol Myers Squibb (BMY), Gilead Sciences (GILD) and Tesla (TSLA). Company Calendar Last Earnings10/29/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 EXEL's financial health is in the Green zone, according to TradeSmith. EXEL has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:EXEL CIK939767 Webwww.exelixis.com Phone(650) 837-7000Fax650-837-8300Employees1,077Year Founded1994Price Target and Rating Average Price Target for Exelixis$58.62 High Price Target$78.00 Low Price Target$41.00 Potential Upside/Downside-10.8%Consensus RatingHold Rating Score (0-4)2.41 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)$3.34 Trailing P/E Ratio19.65 Forward P/E Ratio17.29 P/E Growth1.77Net Income$782.57 million Net Margins35.45% Pretax Margin42.69% Return on Equity45.54% Return on Assets33.90% Debt Debt-to-Equity RatioN/A Current Ratio3.21 Quick Ratio3.14 Sales & Book Value Annual Sales$2.50 billion Price / Sales6.42 Cash Flow$2.90 per share Price / Cash Flow22.63 Book Value$7.52 per share Price / Book8.74Miscellaneous Outstanding Shares244,011,000Free Float237,667,000Market Cap$16.03 billion OptionableOptionable Beta0.45 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:EXEL) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersI wasn't planning on sharing this yet, but here it isMarkham Trading's complete Alpha Oracle Signal system is just $7 for Black Friday. Others paid nearly $2,000 f...TradeWins | SponsoredChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is ...Profits Run | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exelixis With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.